<DOC>
	<DOCNO>NCT02527681</DOCNO>
	<brief_summary>The primary objective characterize pharmacokinetics single dos ceftobiprole neonate infant age ≤ 3 month . The secondary objective evaluate safety tolerability ceftobiprole neonates infant age ≤ 3 month .</brief_summary>
	<brief_title>Pharmacokinetics Safety Ceftobiprole Neonates Infants 3 Months Treated With Systemic Antibiotics</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Ceftobiprole</mesh_term>
	<mesh_term>Ceftobiprole medocaril</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>Neonates infant ≤ 3 month , gestational age ≥ 28 week Documented presumed ( risk ) bacterial infection , currently receive antibiotic treatment Expected survive beyond first 7 day enrolment Sufficient vascular access receive study drug , allow blood sample site separate study drug infusion site Parent 's / legally acceptable representative 's informed consent participate study Major birth defect malformation syndrome Proven presence immunodeficiency HIV congenital viral fungal infection Significant laboratory abnormality include : Haematocrit &lt; 20 % ; Absolute neutrophil count &lt; 0.5⋅10⁹/L ; Platelet count &lt; 50⋅10⁹/L ; Alanine aminotransferase aspartate aminotransferase &gt; 3 time agespecific upper limit normal Impaired renal function know significant renal disease Any condition would make subject caregiver , opinion investigator , unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Months</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>